Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Ono Pharmaceutical Co., Ltd.    4528   JP3197600004


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Ono Pharmaceutical : Selected as a 'Climate Change A List' Company in CDP 2019 for Two Consecutive Years

share with twitter share with LinkedIn share with facebook
share via e-mail
01/21/2020 | 09:59am EST

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director: Gyo Sagara, 'ONO') announced that Ono has been selected as a 'Climate Change A List' company in 2019 by CDP, a globally prestigious organization in the environmental field, for two consecutive years based on its efforts to climate change and information disclosure in 2019.

Ono has established an environmental vision, ECO VISION 2050 (Environment Challenging Ono Vision 2050) based on the 'Ono Pharmaceutical Environmental Guidelines', where Ono has set up its long-term goal to reduce greenhouse gases by 55% by 2030 and 0% by 2050 in Scope 1 + 2, compared to FY2017. Ono makes company-wide efforts to reduce greenhouse gas discharged from our business activities. Ono also aims to reduce emissions in cooperation with our business partners by transmitting information both inside and outside the company

Ono continues to contribute to society by discovering and developing innovative pharmaceutical products, and work toward the realization of a sustainable society.

About CDP

CDP is a global non-profit that drives companies and governments to reduce their greenhouse gas emissions, safeguard water resources and protect forests. Voted number one climate research provider by investors and working with institutional investors with assets of US$96 trillion, we leverage investor and buyer power to motivate companies to disclose and manage their environmental impacts. Over 8,400 companies with over 50% of global market capitalization disclosed environmental data through CDP in 2019. This is in addition to the over 920 cities, states and regions who disclosed, making CDP's platform one of the richest sources of information globally on how companies and governments are driving environmental change. CDP is a founding member of the We Mean Business Coalition.

About a scoring of CDP

CDP's annual environmental disclosure and scoring process is widely recognized as the gold standard of corporate environmental transparency. In 2019, over 525 investors with over US$96 trillion in assets and 125 major purchasers with US$3.6 trillion in procurement spend requested companies to disclose data on environmental impacts, risks and opportunities through CDP's platform and over 8,400 responded.

A detailed and independent methodology is used by CDP to assess these companies, allocating a score of A to D- based on the comprehensiveness of disclosure, awareness and management of environmental risks and demonstration of best practices associated with environmental leadership, such as setting ambitious and meaningful targets. Those that don't disclose or provide insufficient information are marked with an F.

The Climate Change A List is published by CDP each year, alongside the A Lists for leadership on protecting forests and water security. The full list of companies that made this year's CDP Climate Change A List is available here, along with other publicly available company scores: https://www.cdp.net/en/companies/companies-scores

The full methodology and criteria for the Climate Change A List are available on CDP's website at: https://www.cdp.net/en/guidance/guidance-for-companies under 'CDP scoring methodologies 2019'.


Email: publicrelations@ono.co.jp

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
01/28ONO PHARMACEUTICAL CO., LTD. : quaterly earnings release
01/27ONO PHARMACEUTICAL : Announces Result from Phase III Clinical Study Evaluating O..
01/21ONO PHARMACEUTICAL : Selected as a 'Climate Change A List' Company in CDP 2019 f..
2019PFIZER INC. : - U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI..
2019ONO PHARMACEUTICAL : receives 'Platinum Kurumin' Certification as a Company Supp..
2019ONO PHARMACEUTICAL : Receives 2019 Environment Minister's Award for Global Warmi..
2019ONO PHARMACEUTICAL : Submits Supplemental Application for Additional Opdivo Intr..
2019ONO PHARMACEUTICAL : Receives Supplemental Approval of KYPROLIS for Intravenous ..
2019ONO PHARMACEUTICAL : Announces Completion of Cancellation of Treasury Shares
2019BRISTOL-MYERS SQUIBB COMPANY : - Opdivo Demonstrates Statistically Significant O..
More news
Financials (JPY)
Sales 2020 298 B
EBIT 2020 75 567 M
Net income 2020 57 903 M
Finance 2020 82 705 M
Yield 2020 1,83%
P/E ratio 2020 22,1x
P/E ratio 2021 20,7x
EV / Sales2020 4,02x
EV / Sales2021 3,64x
Capitalization 1 281 B
Duration : Period :
Ono Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONO PHARMACEUTICAL CO., LT
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 2 566,67  JPY
Last Close Price 2 566,00  JPY
Spread / Highest target 24,7%
Spread / Average Target 0,03%
Spread / Lowest Target -29,9%
EPS Revisions
Gyo Sagara President & Representative Director
Kei Sano Director & General Manager-Operations
Toichi Takino Managing Executive Officer & GM-Research
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director & Executive Vice President
Sector and Competitors